The result of their subgroup analysis based on PD-L1 expression levels (≥1%, ≥5% and ≥10%) showed that the Nivolumab monotherapy group was superior to the docetaxel second-line chemotherapy group in patients with positive PD-L1 expression (9).The level of PD-L1 expression remains unclear in NSCLC patients resistant to EGFR-TKIs therapy. Here, CD274 is linked to non-small cell lung carcinoma.